RELATED STUDY
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial
Key Findings: This study of adjuvant N-palmitoylethanolamide (PEA) for treating negaative symptoms in patients with schizophrenia found that PEA was safe and effective.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 50
Study Result: Positive
Research Location(s): Iran
Year of Pub: 2022
Cannabinoids Studied: Anandamide (AEA), Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Ligands Studied: Dopamine, Glutamate
Dosage: PEA (600 mg twice a day)
Route of Administration: Oral (Ingestion)
Citation: Salehi A, et al. Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. Psychiatry Res. 2022; 316:114737. doi: 10.1016/j.psychres.2022.114737
Authors: Salehi A, Namaei P, TaghaviZanjani F, Bagheri S, Moradi K, Khodaei Ardakani MR, Akhondzadeh S
